Bullish & Foolish
--
--

Is Aethlon Medical going out of business?

Loading the full analysis
Reading the filings

AETHLON MEDICAL INC (AEMD) Fundamentals

A quick summary of the latest filed figures while the full analysis loads.

AETHLON MEDICAL INC (AEMD) scores 22 out of 100 on fundamentals, Distressed / Caution, based on SEC filing data.

Quality score 22/100
Rating Distressed / Caution
Sector Biotech/Pharma
Market cap $2.9M
Last close $1.82
Revenue growth (YoY) -100.0%
Dividend yield 0.0%

Leading signal: ROIC: -2033.54%

Five questions, kept separate

Survival - Fragile
7-10 mo of estimated runway from 2026-06-30, based on $4.9M of cash and short-term investments against $7.0M of annual burn.
Business quality - Pre-commercial
Operating margins cannot grade a pipeline; Survival and clinical evidence remain the relevant lenses here.
Trajectory - Clinical progress unavailable
Fundamentals can show funding and burn, but not whether the clinical pipeline is advancing.
Valuation - Reasonable
173% net-cash backing support a reasonable pre-commercial Valuation assessment.
Event risk - Evidence unavailable
No active asserted adverse event was found in the available filing evidence. The filing evidence is stale or incomplete, so this is not proof of absence.

What the rules read

  • Debt / Equity: -0.90x (Net Cash)
  • ROIC: -2033.54%
  • Revenue CAGR (3Y): -100.00%
  • Return on Assets: -114.69%
  • Cash Runway (years): 0.70y
  • Price / Earnings: Unprofitable (see Valuation)
  • Effective Tax Rate: 0.00% (loss-making)

Read from filings through 2026-08-13.

Price as of 2026-09-07.

Headline score detail

Source coverage and limitations
--
Reference Links